Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Commercial

Set Alert for Commercial

Killing Targeted Bacteria With CRISPR Drugs Is SNIPR BIOME's Promise

SNIPR BIOME aims to be the world’s top developer of CRISPR-based drugs that selectively target and kill bacteria, while leaving the rest of the patient’s microbiome intact, the biotech’s CEO tells Scrip.

Clinical Trials Infectious Diseases Gastrointestinal

Vasopharm Sees Path Forward For Traumatic Brain Injury Drug

Vasopharm’s ronopterin (VAS203) missed its primary endpoint in the Phase III NOSTRA III study in patients with traumatic brain injury, but further analyses point to a significant clinical benefit when the inducible NOS inhibitor is given within 12 hours of trauma, suggesting a role for the compound in the condition.

Neurology Clinical Trials Research & Development

Companies

Set Alert for Companies

Latest From Companies

GSK Makes ADC Pipeline Comeback With Mersana Deal

The UK major has teamed up with the US biotech to develop the latter’s HER-2 targeted antibody-drug conjugate, a couple of years after the approval of Blenrep, in what is becoming an increasingly competitive space.

Companies Deals

New Era For Schizophrenia Therapy Beckons As Karuna Soars On Promising Phase III Data

The PureTech Health-founded entity believes it has made a significant step forward in the treatment of schizophrenia with its muscarinic-receptor acting agent KarXT, which could offer a completely new way to address all three symptom domains of the disease.

Clinical Trials Companies

Novo Touts Diabetes R&D As Ozempic Faces Lilly Challenger

The Danish major highlighted a spate of diabetes pipeline updates during its second quarter earnings as blockbuster drug Ozempic grappled with a new rival in the shape of Lilly’s Mounjaro.

Companies Metabolic Disorders

Stock Watch: Pfizer’s Second-Quarter Pandemic And Base Businesses Diverge

Pfizer recorded the largest quarterly sales in its history as its COVID-19 franchise easily outweighed the currency issues that are challenging other companies. But expectations for a quick end to the pandemic have wiped these gains from Pfizer’s stock price.

Stock Watch Companies

AdipoPharma Targets Root Cause Of Diabetes With First ‘Adipeutic’ Drug Candidate

Emerging Company Profile: The French biotech is developing a constrained peptide that targets an interaction in body fat tissue in the hopes of treating type 2 diabetes.

Emerging Company Profile Metabolic Disorders

Amgen’s $3.7bn ChemoCentryx Buy May Help Offset Growing Pains

Amgen is acquiring a pipeline-in-a-pill with ChemoCentryx’s Tavneos, currently approved for ANCA-associated vasculitis, at a time when the company’s existing portfolio is struggling to maintain sales growth.

Growth M & A
See All

Deals

Set Alert for Deals

Latest From Deals

GSK Makes ADC Pipeline Comeback With Mersana Deal

The UK major has teamed up with the US biotech to develop the latter’s HER-2 targeted antibody-drug conjugate, a couple of years after the approval of Blenrep, in what is becoming an increasingly competitive space.

Companies Deals

Pfizer’s Buying Spree Continues With GBT, Gaining A Sickle Cell Disease Franchise

Pfizer has reached a deal to buy Global Blood Therapeutics for $5.4bn, gaining the sickle cell therapy Oxbryta and building on efforts to reach underserved patient groups.

Blood & Coagulation Disorders Deals

Sanofi, Innovent Link On China Oncology Ambitions As ADCs Surge

The antibody-drug conjugate market is emerging as the next battleground for intense competition in China, with global partnerships becoming essential to win, as evidenced by a major new alliance between Innovent and Sanofi.

China Deals

Amgen’s $3.7bn ChemoCentryx Buy May Help Offset Growing Pains

Amgen is acquiring a pipeline-in-a-pill with ChemoCentryx’s Tavneos, currently approved for ANCA-associated vasculitis, at a time when the company’s existing portfolio is struggling to maintain sales growth.

Growth M & A

Gilead Grabs MiroBio's Checkpoint Agonists For $405m

Just over a month after raising $97m in a series B round, Oxford University spinout MiroBio and its immune checkpoint agonists have been snapped up by Gilead Sciences. 

M & A Immune Disorders

Sosei Bolsters GPCR Focus With AbbVie Neurology Deal

The Japanese firm has expanded its partnership with AbbVie into the neurology space, where it hopes to use its unique platform technology to develop up to three drug candidates targeting ‘challenging’ G protein-coupled receptor targets.

Deals Cancer
See All

Strategy

Set Alert for Strategy

Latest From Strategy

Verona Transformed After Phase III Victory For COPD Therapy

The UK firm's ensifentrine has exceeded analyst expectations by cutting the rate of moderate to severe COPD exacerbations by 42% over 24 weeks.

Clinical Trials Respiratory

Dr Reddy’s Gears For Generic Revlimid Run In US, Quarterly ‘Blips’ Aside

Quarterly ups and down notwithstanding, Dr Reddy’s signals continuing US launch momentum, with its generic Revlimid, for which the Indian firm claims exclusivity for two strengths, set to hit the market next month. “Low competition” assets, especially injectables, also continue to be on the deal-making radar in the US.

Commercial India

Alnylam Ready To Expand TTR Franchise With Positive Cardiomyopathy Results

ATTR amyloidosis patients with cardiomyopathy had statistically significant functional and quality of life improvements when treated with Onpattro (patisiran) in the Phase III APOLLO-B study.

Clinical Trials Strategy

Torrent To Build ‘Future Brazil’ In Mexico, Open To Acquisitions In India

Torrent is upping its ambitions in Mexico, the second-largest market in Latin America, where it is to set up a manufacturing hub along with other Indian companies. As sales in the US stagnate, it's also on the acquisition path in India. Meanwhile, building market share for its Januvia generic is going to be an uphill task.

Commercial Business Strategies

Kazia Suffers Brain Cancer Drug Setback But All Hope Not Lost

News that the Australian biotech's paxalisib did not meet pre-defined criteria to continue into the second stage of a major glioblastoma platform trial saw Kazia's stock crash, but investor reaction appears to be excessive.

Clinical Trials Cancer

Amid Expected Enhertu Entry, Chinese Domestic ADC Developers Race To Market

12 biotechs in China are preparing to compete for domestic market share for their home-grown HER2-targeted antibody-drug conjugates amid Enhertu’s in-roads in the country.

China Strategy
See All

Market Access

Set Alert for Market Access

Latest From Market Access

Sarepta Pursues DMD Gene Therapy Accelerated Approval To Be First To Market

Sarepta has experience pursuing accelerated approvals in the US for Duchenne muscular dystrophy therapies, but with a costly gene therapy will payers require data from a controlled Phase III study?

Gene Therapy Reimbursement

Alnylam Stays Mum On APOLLO-B Amid Anticipation Over Major Readout

The company announced a respectable increase in second quarter sales and expects to announce topline results within the next three weeks for the Phase III trial of Onpattro in ATTR-CM.

Sales & Earnings Business Strategies

Bristol’s New Products Meet Early Launch Expectations

Sales rose significantly for Reblozyl and for Abecma and Breyanzi, despite manufacturing challenges for the two cell therapies. Newly approved Opdualag and Camzyos are off to encouraging starts.

Growth Launches
See All

Market Intelligence

Set Alert for Market Intelligence

Latest From Market Intelligence

Titans Of Pharma 2022: Johnson & Johnson Pays Highest Exec Compensation Again

Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.

Companies Leadership

MS Market Snapshot: New Options Confront Commercial Reality Of A Crowded Space

The multiple sclerosis drug market is more competitive than ever, though new options work through existing mechanisms of action. Unmet need remains despite numerous drugs, and competition clustered in the same classes creates pressure.

Immune Disorders Market Intelligence

PARP Inhibitor Market Dynamics: A Podcast

PARP inhibitors are expected to generate $10bn in sales by 2030. Datamonitor Healthcare analysts discuss their positioning in breast, ovarian, pancreatic and prostate cancer, looking at the current market landscape and future strategies.

Cancer Market Intelligence
See All
UsernamePublicRestriction

Register